A New Class of Multitargeting PtIV Anticancer Agents: Prodrugs That Release PtII Drugs and Bioactive Moieties Tethered to PtIV via a Tertiary Amine

In most multi-action PtIV prodrugs previously reported, the bioactive molecules have carboxylate, hydroxyl, primary, or secondary amine groups through which they are tethered to the axial position of the PtIV directly or via self-immolative linkers. A major challenge is to expand the range to bioactive molecules that can be released in their active form from PtIV prodrugs to molecules having a tertiary amine. Herein, we describe the general approach for design and synthesis of PtIV complexes conjugated to organic drugs (brigatinib, osimertinib, adavosertib, and irinotecan) via their tertiary amines. The complexes are stable and release the active drugs upon reduction. The PtIV prodrugs conjugated to tyrosine kinase inhibitors (TKIs) showed potent anticancer activity in 2D and 3D cancer models by combining the modes of action of platinum and TKi. They inhibited in vivo tumor growth in an LLC model better than brigatinib, osimertinib, and cisplatin with significantly lower body weight loss.